ストックスクリーナーアプリを入手
1.72
0.08%
0.00
Annovis Bio Inc (ANVS) 最新ニュース
CCORF Maintains Annovis Bio(ANVS.US) With Buy Rating, Maintains Target Price $17 - Moomoo
symbol__ Stock Quote Price and Forecast - CNN
Annovis Bio (NYSE:ANVS) Given "Buy" Rating at Canaccord Genuity Group - MarketBeat
Annovis Bio stock price target reiterated at $17 by Canaccord - Investing.com
Annovis Bio Inc (ANVS) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey
Certain Stock Options of Annovis Bio, Inc. are subject to a Lock-Up Agreement Ending on 17-AUG-2026. - marketscreener.com
Annovis Bio (ANVS) Advances 3.35% as Shares Test Key Resistance Near $1.94Volume Profile - vinanet.vn
Annovis Bio (NYSE:ANVS) Posts Quarterly Earnings Results, Beats Estimates By $0.04 EPS - MarketBeat
Annovis Bio (ANVS) posts $32.4M loss and warns on going-concern risk - Stock Titan
ANVS: Net loss rose sharply as clinical trial costs surged, with cash runway only through Q4 2026 - TradingView
Annovis Bio | 10-Q: Q2 2026 Earnings Report - Moomoo
ANVS: Alzheimer's Phase 3 trial fully enrolled; R&D costs and net loss per share increased year-over-year - tradingview.com
Annovis Reports $14.8 Million Q2 Loss as Phase 3 AD Trial Fully Enrolls - Quiver Quantitative
Highbridge Capital (ANVS) discloses 6.1% Annovis Bio stake tied to 2.78M warrant shares - Stock Titan
Annovis Bio | SCHEDULE 13G: Others - Moomoo
Annovis Bio Sees Unusually Large Options Volume (NYSE:ANVS) - MarketBeat
Annovis Bio Q2 EPS of $(0.40) beats $(0.45) estimate - scanx.trade
Annovis Bio Inc reports results for the quarter ended June 30Earnings Summary - TradingView
Annovis Provides Corporate Updates and Second Quarter 2026 Financial Results - The Manila Times
ANNOVIS BIO Q2 EPS USD -0.4 - Moomoo
Press Release: Annovis Provides Corporate Updates and Second Quarter 2026 Financial Results - Moomoo
Annovis Bio, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2026 - marketscreener.com
Empery Asset Management, LP's Annovis Bio Inc(ANVS) Holding History - GuruFocus
Annovis Bio (ANVS) Holds Ground at $1.79, Testing Critical Support in a Cautious Biotech MarketOn Balance Volume - vinanet.vn
Annovis Bio, Inc. (ANVS) options chain - Yahoo Finance Singapore
Annovis Bio (ANVS) Edges Lower But Holds Above Key Support at $1.78Overvalued Signals - vinanet.vn
Annovis Bio Inc (ANVS) Stock News Today - TradingKey
Annovis Bio Inc expected to post a loss of 45 cents a shareEarnings Preview - TradingView
Annovis Bio (ANVS) Projected to Post Quarterly Earnings on Tuesday - MarketBeat
Annovis Bio, Inc. (NYSE:ANVS) Given Average Rating of "Moderate Buy" by Analysts - MarketBeat
Annovis Bio (ANVS) Rallies 5% as Stock Approaches Key ResistanceVolume Breadth - dars.gov.et
Annovis Bio (ANVS): Empery Asset Management discloses 5.64% beneficial stake - Stock Titan
ANVS|Annovis Bio Inc|Price:1.665|Chg%:+0.005 - TradingKey
Annovis Bio Inc (ANVS) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey
Annovis Bio Inc (ANVS) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey
Annovis Bio Inc (ANVS) Institutional Confidence - TradingKey
Annovis Bio Inc (ANVS) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
Annovis Bio (ANVS) Gains 1.8% as Shares Hold Above Key Support at $1.61Short Term Trading Ideas - dars.gov.et
Annovis Bio Inc (ANVS) Cash Flow - TradingKey
Annovis Bio Inc (ANVS) Financial Health: Profitability & Balance Sheet Analysis - TradingKey
Annovis Bio Inc (ANVS) Income Statement - TradingKey
Annovis Bio Inc (ANVS) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
Annovis Bio Inc (ANVS) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
ANVS|Annovis Bio Inc|Price:1.650|Chg%:-0.100 - TradingKey
ANVS|Annovis Bio Inc|Price:1.686|Chg%:+0.026 - TradingKey
Annovis Bio Inc (ANVS) Valuation: PE, PB & Fair Value Analysis - TradingKey
Annovis Bio, Inc. Revenue Breakdown – NYSE:ANVS - TradingView
ANVS stock holds support after recent clinical update - Ad-hoc-news.de
Annovis Bio (ANVS) Slips 0.57% to $1.74 as Stock Hovers Near Key SupportOvernight Profile - dars.gov.et
Annovis Bio (ANVS) Sits Near Support With Slight Decline: Key Levels in FocusStatistical Arbitrage - po-news-eg.net
Annovis Completes Enrollment for Alzheimer’s Phase 3 Trial - MyChesCo
Annovis Bio enrolls over 850 patients for its next Alzheimer's Disease trial - qz.com
Annovis Bio Completes Enrollment for Pivotal Phase 3 Alzheimer’s Trial, Plans NDA Submissions in 2027 and 2028 12 - Minichart
Annovis Bio Completes Enrollment in Pivotal Alzheimer’s Trial - TipRanks
Annovis Reaches Full Enrollment in Phase 3 Buntanetap Trial, 850 Patients Enrolled - TradingView
Annovis Bio (NYSE: ANVS) completes enrollment in 850-patient Phase 3 Alzheimer’s study - Stock Titan
Roth MKM Maintains Annovis Bio(ANVS.US) With Buy Rating, Maintains Target Price $8 - Moomoo
Analysts’ Top Healthcare Picks: Evolus (EOLS), Annovis Bio (ANVS) - The Globe and Mail
Annovis Promotes Research Chief as Lead Drug Nears Key Trial - MyChesCo
Annovis Bio Edges Higher, Holds Support at $1.84Profit Surge Picks - dars.gov.et
1.01%
1.59%
大文字化:
|
ボリューム (24 時間):